Oral contraceptives vs injectable progestin in their effect on sexual behavior

被引:17
作者
Schaffir, Jonathan A. [1 ]
Isley, Michelle M. [1 ]
Woodward, Megan [1 ]
机构
[1] Ohio State Univ, Coll Med, Dept Obstet & Gynecol, Columbus, OH 43210 USA
关键词
combined oral contraceptives; depot medroxyprogesterone acetate; sexual function; side effects; HORMONE-BINDING GLOBULIN; FUNCTION INDEX FSFI; ANDROGEN LEVELS; MEDROXYPROGESTERONE ACETATE; PREMENOPAUSAL WOMEN; DYSFUNCTION; IMPACT; TESTOSTERONE; LIBIDO;
D O I
10.1016/j.ajog.2010.07.024
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: We sought to compare sexual function and hormone concentrations in combined oral contraceptive (COC) and injectable progestin users. STUDY DESIGN: Sexually active COC and depot medroxyprogesterone acetate (DMPA) users completed the Female Sexual Function Index (FSFI) questionnaire, a demographic data form, and had serum testosterone and estradiol levels measured. Multiple linear regression was used to measure associations of interest. RESULTS: Among 50 subjects enrolled, COC users had lower levels of free testosterone compared to DMPA users (0.2 vs 0.6 pg/mL; P < .0001) and higher levels of estradiol (75.8 vs 62.8 pg/mL; P = .0057), but scores of desire (4.2 vs 3.8; P = .27), scores of arousal (5.0 vs 4.8; P = .46), or total scores (30.1 vs 28.8; P = .28) were no different. Demographic characteristics were similar except for ethnicity, level of education, gravidity, parity, and frequency of intercourse. In multivariate analysis, birth control type was not significantly associated with desire score or total FSFI score. CONCLUSION: While users of COC and DMPA have significantly different sex hormone levels, they are not different in sexual function as measured by the FSFI.
引用
收藏
页码:545.e1 / 545.e5
页数:5
相关论文
共 50 条
  • [1] The influence of combined oral contraceptives on female sexual desire: A systematic review
    Pastor, Zlatko
    Holla, Katerina
    Chmel, Roman
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2013, 18 (01) : 27 - 43
  • [2] Effect of Injectable and Oral Contraceptives on Serum Lipids
    Berenson, Abbey B.
    Rahman, Mahbubur
    Wilkinson, Gregg
    OBSTETRICS AND GYNECOLOGY, 2009, 114 (04) : 786 - 794
  • [3] Effect of Injectable and Oral Contraceptives on Glucose and Insulin Levels
    Berenson, Abbey B.
    van den Berg, Patricia
    Williams, Karen J.
    Rahman, Mahbubur
    OBSTETRICS AND GYNECOLOGY, 2011, 117 (01) : 41 - 47
  • [4] Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer
    Strom, BL
    Berlin, JA
    Weber, AL
    Norman, SA
    Bernstein, L
    Burkman, RT
    Daling, JR
    Deapen, D
    Folger, SG
    Malone, KE
    Marchbanks, PA
    Simon, MS
    Ursin, G
    Weiss, LK
    Spirtas, R
    CONTRACEPTION, 2004, 69 (05) : 353 - 360
  • [5] Risk of sexual dysfunction with progestin-based contraceptives in women of child-bearing age
    Guo, Michael Y.
    Sodhi, Mohit
    Khosrow-Khavar, Farzin
    Etminan, Mahyar
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (01) : 133 - 140
  • [6] Change to Either a Nonandrogenic or Androgenic Progestin-Containing Oral Contraceptive Preparation is Associated with Improved Sexual Function in Women with Oral Contraceptive-Associated Sexual Dysfunction
    Davis, Susan R.
    Bitzer, Johannes
    Giraldi, Annamaria
    Palacios, Santiago
    Parke, Susanne
    Serrani, Marco
    Mellinger, Uwe
    Nappi, Rossella E.
    JOURNAL OF SEXUAL MEDICINE, 2013, 10 (12) : 3069 - 3079
  • [7] Combined estrogen-progestin oral contraceptives and female sexuality: an updated review
    Krapf, Jill M.
    Goldstein, Andrew T.
    SEXUAL MEDICINE REVIEWS, 2024, 12 (03) : 307 - 320
  • [8] Sexual function and combined oral contraceptives: a randomised, placebo-controlled trial
    Lundin, Cecilia
    Malmborg, Agota
    Slezak, Julia
    Danielsson, Kristina Gemzell
    Bixo, Marie
    Bengtsdotter, Hanna
    Marions, Lena
    Lindh, Ingela
    Theodorsson, Elvar
    Hammar, Mats
    Sundstrom-Poromaa, Inger
    ENDOCRINE CONNECTIONS, 2018, 7 (11): : 1208 - 1216
  • [9] Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation
    Bastianelli, Carlo
    Farris, Manuela
    Rosato, Elena
    Brosens, Ivo
    Benagiano, Giuseppe
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (11) : 1085 - 1098
  • [10] Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis
    Farris, Manuela
    Bastianelli, Carlo
    Rosato, Elena
    Brosens, Ivo
    Benagiano, Giuseppe
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (10) : 1129 - 1144